Sialix Closes Oversubscribed Second Tranche of Series B Financing

Sialix, Inc., a biotechnology company developing products for the treatment and prevention of cancer, today announced the closing of an oversubscribed $1.2 million tranche of an angel-led financing. Among the investors were several angel investment groups including the Desert Angels.

“Building a biotech company today is challenging, and at this stage we have chosen to maintain a lean structure that can be supported with angel funding. It is terrific and validating to get such strong support from a wide variety of angel groups,” said Jeff Behrens, Sialix’s CEO.

Read more: Sialix Closes Oversubscribed Second Tranche of Series B Financing